RecruitingPhase 1NCT06485505

Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis

Efficacy of Low Dose Isotretinoin Versus Excimer Light as an Adjuvant for Itraconazole in Treatment of Onychomycosis: a Randomized Controlled Trial.


Sponsor

Zagazig University

Enrollment

36 participants

Start Date

Jul 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

3 groups of patients with onychomycosis will be recruited. Group A will receive itraconazole alone. Group B will receive itraconazole + low dose isotretinoin and group C will be treated with itraconazole + excimer light sessions.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria1

  • patients with onychomycosis

Exclusion Criteria1

  • pregnant and lactating females patients on statin therapy or photosensitizing drugs patients with liver disease, heart disease and diabetes milletus.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGISOtretinoin 10 MG

Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis

DEVICEexcimer light

excimer light as an adjuvant for itraconazole in treating onychomycosis

DRUGItraconazole 200 mg

Itraconazole alone


Locations(1)

Zagazig University Hospitals

Zagazig, Zagazig, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06485505


Related Trials